This collection examines Europe’s harm reduction journey, including early successes, uneven implementation, securitisation, stigma and medicalisation; and proposes a reframed, people-led approach centring wellbeing, acknowledging drug-use benefits, and advancing rights-based reforms.
The New Zealand Drug Foundation urges reform of outdated drug laws, calling for decriminalisation, Māori-led health approaches and investment in harm reduction to build safer, fairer, evidence-based policies for Aotearoa New Zealand.
This dialogue at SOAS explores the coca leaf beyond prohibition — as a bridge between Indigenous knowledge, environmental justice, and drug policy reform. Featuring voices from Colombia and beyond.
IDPC calls on the European Commission to ensure the next Strategy is balanced, evidence-based, and rights-centred, prioritising harm reduction, civil society participation, and policy innovation over punitive approaches.
International cooperation through the Association of Southeast Asian Nations presents an opportunity to consistently align regional drug policy with human rights standards.
Amid a rapidly shifting diplomatic landscape, Colombia has emerged as a potential leader of global non-prohibitionist drug policy reform, but the sustainability of these efforts remains uncertain.
Ten Dutch municipalities will be permitted to sell only legally produced hashish. Experts suggest demand for Moroccan hashish will continue, driving the market out of the shops and into the streets
Bewley-Taylor et al. find the GDPI useful for comparing international drug policy, and suggest improvements to better handle uncertainty and diverse data.
Mulcahy et al. explore whether stigma constitutes cruel, inhuman, and degrading treatment, outlining possibilities for viable legal claims on the basis of human rights.
